Product Information
ENOXAPARIN 300 MG/3 ML VIAL is a generic product labeled by Sanofi-Aventis U.S. LLC, priced at $9.8724 per ML under NDC 00955101601. Its NADAC has been published 472 times since Dec 18, 2013.
FDA first approved this application on Mar 29, 1993. Its Orange Book therapeutic-equivalence code is AP.
The High Outlier badge above means this manufacturer's average price in the enoxaparin sodium market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
300 mg/3mL
Manufacturer
Sanofi-Aventis U.S. LLCNDC
00955101601
Classification
Generic
Dosage Form
INJECTION
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Active Ingredients
ENOXAPARIN SODIUMApproval Type
Authorized Generic (NDA)
FDA Application
NDA020164FDA Approved
3/29/1993
TE Code
AP
On Market Since
10/3/2011
Pharmacological Classes
Price Statistics
The NADAC for ENOXAPARIN 300 MG/3 ML VIAL has been published 472 times since Dec 18, 2013, and over the history we have for it it has declined 80.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.8724 per ML |
|---|---|
| All-time high | $68.5340 (Feb 11, 2015) |
| All-time low | $9.8724 (Sep 23, 2026) |
| 52-week high | $11.6405 |
| 52-week low | $9.8724 |
| Median price | $15.7340 |
| Average price | $24.2212 |
| Largest weekly change | -45.9% (Aug 23, 2017) |
| Weeks tracked | 472 |
| Tracking since | Dec 18, 2013 |
Generic Alternatives
The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sanofi-Aventis U.S. LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
enoxaparin sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Low Molecular Weight Heparin class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ENOXAPARIN 300 MG/3 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for ENOXAPARIN 300 MG/3 ML VIAL, manufactured by Sanofi-Aventis U.S. LLC, is $9.8724 per ML (NDC 00955101601), effective Sep 30, 2026.
How has the price of ENOXAPARIN 300 MG/3 ML VIAL changed over time?
Over the history we have for it, the NADAC for ENOXAPARIN 300 MG/3 ML VIAL has declined 80.5%. It has been tracked across 472 weekly CMS publications since Dec 18, 2013.
What are the highest and lowest recorded NADAC prices for ENOXAPARIN 300 MG/3 ML VIAL?
Since Dec 18, 2013, the NADAC for ENOXAPARIN 300 MG/3 ML VIAL has ranged from a low of $9.8724 (Sep 23, 2026) to a high of $68.5340 (Feb 11, 2015), with a median of $15.7340 per ML.
Are there cheaper alternatives to ENOXAPARIN 300 MG/3 ML VIAL?
3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ENOXAPARIN 300 MG/3 ML VIAL in a comparable dosage form, but none are currently priced below it.
Who manufactures ENOXAPARIN 300 MG/3 ML VIAL?
ENOXAPARIN 300 MG/3 ML VIAL (NDC 00955101601) is labeled by Sanofi-Aventis U.S. LLC, and CMS classifies it as a generic product.